Published in N Engl J Med on December 04, 2003
Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. P T (2012) 1.19
Low rates of clinical recurrence after biopsy of benign to moderately dysplastic melanocytic nevi. J Am Acad Dermatol (2009) 1.03
Atypical mole syndrome and dysplastic nevi: identification of populations at risk for developing melanoma - review article. Clinics (Sao Paulo) (2011) 0.97
Melanocytic dysplastic naevi occupy the middle ground between benign melanocytic naevi and cutaneous malignant melanomas: emerging clues. J Clin Pathol (2005) 0.90
Promoter CpG island hypermethylation in dysplastic nevus and melanoma: CLDN11 as an epigenetic biomarker for malignancy. J Invest Dermatol (2014) 0.85
The epidemiology, prevention, and detection of melanoma. Ochsner J (2010) 0.81
Dysplastic nevi. N Engl J Med (2004) 0.77
State of melanoma: an historic overview of a field in transition. Hematol Oncol Clin North Am (2014) 0.76
Primary Gingival Melanoma: An Important Entity. J Maxillofac Oral Surg (2015) 0.75
Dysplastic nevi. N Engl J Med (2004) 0.75
Dysplastic nevi. N Engl J Med (2004) 0.75
A case of dysplastic nevus of the external auditory canal presenting with conductive hearing loss. Yonsei Med J (2009) 0.75
Predictive Nuclear Chromatin Characteristics of Melanoma and Dysplastic Nevi. J Pathol Inform (2017) 0.75
Clinical and histological characteristics of melanocytic nevus in external auditory canals and auricles. Eur Arch Otorhinolaryngol (2013) 0.75
In vivo vitiligo induction and therapy model: double-blind, randomized clinical trial. Pigment Cell Melanoma Res (2011) 1.50
Acute generalized exanthematous pustulosis: an overview of the clinical, immunological and diagnostic concepts. Eur J Dermatol (2010) 1.36
EGFR in melanoma: clinical significance and potential therapeutic target. J Cutan Pathol (2011) 1.32
The role of RhoC in growth and metastatic capacity of melanoma. J Cutan Pathol (2009) 0.95
Cancer risk in immune-mediated inflammatory diseases (IMID). Mol Cancer (2013) 0.95
miR-145 overexpression suppresses the migration and invasion of metastatic melanoma cells. Int J Oncol (2013) 0.95
Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients. Eur J Cancer (2011) 0.93
The role of VEGF-C staining in predicting regional metastasis in melanoma. Virchows Arch (2008) 0.91
Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports. Endocrine (2014) 0.86
Melanocyte-specific immune response in a patient with multiple regressing nevi and a history of melanoma. Anticancer Res (2011) 0.83
Clinical significance of the expression of c-Ski and SnoN, possible mediators in TGF-beta resistance, in primary cutaneous melanoma. J Dermatol Sci (2008) 0.83
Efficacy of products to remove eggs of Pediculus humanus capitis (Phthiraptera: Pediculidae) from the human hair. J Med Entomol (2014) 0.82
P-cadherin counteracts myosin II-B function: implications in melanoma progression. Mol Cancer (2010) 0.81
Method to measure force required to remove Pediculus humanus capitis (Phthiraptera: Pediculidae) eggs from human hair. J Med Entomol (2005) 0.79
A short dermoscopy training increases diagnostic performance in both inexperienced and experienced dermatologists. Australas J Dermatol (2014) 0.79
Knowledge and management of scabies in general practitioners and dermatologists. Eur J Dermatol (2005) 0.78
Immune mediated mechanisms of melanocyte destruction: Paving the way for efficient immunotherapeutic strategies against melanoma. Oncoimmunology (2012) 0.78
Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients: failure at the effector phase? Melanoma Res (2015) 0.78
Association of haptoglobin phenotypes with the development of Kaposi's sarcoma in HIV patients. Arch Dermatol Res (2011) 0.77
Three-dimensional skin models as tools for transdermal drug delivery: challenges and limitations. Expert Opin Drug Deliv (2011) 0.75
Superficial granulomatous pyoderma with ocular involvement. Eur J Dermatol (2010) 0.75
Successful Treatment of HCV-associated B-Cell Non-Hodgkin Lymphomas With Direct-acting Antiviral Agents. J Clin Gastroenterol (2016) 0.75